New Trial Protocol to Test Tirzepatide for Obesity in Type 1 Diabetes Patients
Background
Obesity is a significant comorbidity in individuals with Type 1 Diabetes (T1D), increasing risks for cardiovascular disease and worsening glycemic control. While tirzepatide, a dual GIP and GLP-1 receptor agonist, is approved for Type 2 Diabetes (T2D) and obesity, its safety and efficacy specifically in the T1D population remain largely unknown. This study protocol addresses the critical need to evaluate tirzepatide's potential as an obesity treatment in patients with Type 1 Diabetes, where current options are limited and concerns about glycemic stability exist.
Study Design
This publication outlines the protocol for a Phase 2, single-center, placebo-matched randomized controlled trial (NCT ID: NCT06180616) designed to investigate the efficacy and safety of tirzepatide in adults with Type 1 Diabetes and concurrent overweight or obesity. The trial, sponsored by Royal North Shore Hospital, plans to enroll an estimated 40 participants who will be randomized to receive either tirzepatide or placebo. Participants will follow a specific dosing regimen, likely involving a titration phase up to a maintenance dose (e.g., 5 mg, 10 mg, or 15 mg weekly), over a period of approximately 2 years, with a start date of December 2026 and completion by December 2028.
Results
As a protocol, this study aims to establish key findings rather than reporting them. The primary outcome measure will be the change in body weight from baseline, with the expectation of significant weight reduction. Secondary endpoints will include changes in glycemic control (e.g., HbA1c, time in range), insulin requirements, and various safety parameters. The trial's most important objective is to determine if tirzepatide can achieve a clinically meaningful reduction in body weight (e.g., >5% or >10% from baseline) in Type 1 Diabetes patients without compromising glycemic stability or increasing severe hypoglycemic events. Researchers anticipate that tirzepatide will lead to a significant decrease in body weight compared to placebo, potentially reducing insulin dose requirements and improving cardiovascular risk factors. The study will also closely monitor adverse events, particularly hypoglycemia, to ensure the medication's safety profile in this vulnerable population.
Key Findings
- The primary endpoint of this Phase 2 trial is to assess the change in body weight from baseline, aiming for a clinically significant reduction (e.g., >5% or >10%) in Type 1 Diabetes patients with obesity.
- Secondary endpoints include evaluating the impact of tirzepatide on glycemic control (e.g., HbA1c, time in range) and insulin requirements, expecting potential improvements while maintaining safety.
- The study will meticulously monitor safety outcomes, particularly the incidence of hypoglycemia and other adverse events, to ensure tirzepatide's tolerability in the Type 1 Diabetes population.
- The trial, running from December 2026 to December 2028 with 40 estimated participants, seeks to establish foundational data for future, larger studies on tirzepatide in T1D.
Why It Matters
This trial is crucial because it seeks to provide a much-needed treatment option for obesity in individuals with Type 1 Diabetes, a population with limited pharmacological interventions. A successful outcome could significantly improve metabolic health and reduce long-term complications for these patients. If proven safe and effective, tirzepatide could become a valuable therapeutic strategy, potentially moving towards larger Phase 3 human trials and eventual clinical use for managing weight in T1D. This would represent a major advancement in the comprehensive care of Type 1 Diabetes.